Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 16/20 | 0.56 |
| ▸ | SCTR | P47872 | 1/20 | 0.56 |
| ▸ | GCGR | P47871 | 1/20 | 0.53 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.52 |
| ▸ | CALCR | P30988 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30207768 | 1.00 | GLP1R (0.56) | GLP1RSCTRGCGROPRL1CALCR | |
| SCHEMBL30320221 | 1.00 | GLP1R (0.56) | GLP1RSCTRGCGROPRL1CALCR | |
| SCHEMBL30320200 | 1.00 | GLP1R (0.56) | GLP1RSCTRGCGROPRL1CALCR | |
| SCHEMBL30320225 | 1.00 | GLP1R (0.56) | GLP1RSCTRGCGROPRL1CALCR | |
| SCHEMBL30320255 | 0.99 | GLP1R (0.55) | GLP1RSCTRGCGROPRL1 | |
| SCHEMBL30108346 | 0.97 | GLP1R (0.59) | GLP1RSCTRGCGRCALCR | |
| SCHEMBL31347304 | 0.97 | GLP1R (0.55) | GLP1RSCTRGCGR | |
| SCHEMBL30637757 | 0.94 | GLP1R (0.53) | GLP1RSCTRGCGR | |
| SCHEMBL29554395 | 0.94 | GLP1R (0.63) | GLP1RSCTR | |
| SCHEMBL29994110 | 0.93 | CALCR (0.58) | GLP1RSCTRGCGRCALCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4724472-A2 | GLP-1/GIP DUAL, GLP-1/GCG DUAL AND GLP-1/GIP/GCG TRIPLE RECEPTOR AGONISTS | Sun Pharmaceutical Industries Limited (IN) | 2026-04-15 | — | — | EP | disclosed |
| CN-115073582-B | Polypeptide compound and application thereof in preventing or treating diabetes or diabetic complications | 深圳市图微安创科技开发有限公司 | 2024-12-20 | — | — | CN | disclosed |
| WO-2024252367-A2 | NOVEL GLP-1/GIP DUAL AND GLP-1/GCG DUAL RECEPTOR AGONISTS | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2024-12-12 | — | — | WO | disclosed |
| CN-114945589-B | Polypeptide compound and application thereof in preventing or treating diabetes or diabetic complications | 深圳市图微安创科技开发有限公司 | 2024-05-24 | — | — | CN | disclosed |
| US-20230183310-A1 | Polypeptide Compounds and Use Thereof in the Prevention or Treatment of Diabetes or Diabetic Complications | SHENZHEN TURIER BIOTECH CO., LTD (CN) | 2023-06-15 | — | — | US | disclosed |
| CN-115073582-A | Polypeptide compound and application thereof in preventing or treating diabetes or diabetic complications | 深圳市图微安创科技开发有限公司 | 2022-09-20 | — | — | CN | disclosed |
| CN-114945589-A | Polypeptide compound and application thereof in preventing or treating diabetes or diabetic complications | 深圳市图微安创科技开发有限公司 | 2022-08-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183310-A1 | Polypeptide Compounds and Use Thereof in the Prevention or Treatment of Diabetes or Diabetic Complications | IAPP, PNLIP, DPP4 | GLP1R 23/4885SCTR 177/4885GCGR 128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.